Systems biology approaches to identify driver genes and drug combinations for treating COVID-19.

Publication date: Jan 26, 2024

Corona virus 19 (Covid-19) has caused many problems in public health, economic, and even cultural and social fields since the beginning of the epidemic. However, in order to provide therapeutic solutions, many researches have been conducted and various omics data have been published. But there is still no early diagnosis method and comprehensive treatment solution. In this manuscript, by collecting important genes related to COVID-19 and using centrality and controllability analysis in PPI networks and signaling pathways related to the disease; hub and driver genes have been identified in the formation and progression of the disease. Next, by analyzing the expression data, the obtained genes have been evaluated. The results show that in addition to the significant difference in the expression of most of these genes, their expression correlation pattern is also different in the two groups of COVID-19 and control. Finally, based on the drug-gene interaction, drugs affecting the identified genes are presented in the form of a bipartite graph, which can be used as the potential drug combinations.

Open Access PDF

Concepts Keywords
Controllability Caused
Covid Combinations
Driver Corona
Genes Covid
Virus Disease
Driver
Drug
Expression
Identified
Identify
Public
Related
Systems
Treating
Virus

Semantics

Type Source Name
disease MESH COVID-19
drug DRUGBANK Huperzine B
disease VO gene
disease MESH Long Covid
drug DRUGBANK Coenzyme M
disease IDO process
drug DRUGBANK Trestolone
disease VO efficiency
disease IDO intervention
disease VO effective
pathway REACTOME Methylation
drug DRUGBANK Aspartame
pathway KEGG Coronavirus disease
disease IDO homo sapiens
disease IDO algorithm
disease IDO blood
drug DRUGBANK Digitoxin
drug DRUGBANK Raloxifene
drug DRUGBANK Sunitinib
drug DRUGBANK Ceritinib
drug DRUGBANK Crizotinib
drug DRUGBANK Ruxolitinib
drug DRUGBANK Tofacitinib
drug DRUGBANK Nintedanib
disease MESH lifestyle
drug DRUGBANK Niacin
drug DRUGBANK Entacapone
disease MESH extensively drug resistant tuberculosis
pathway KEGG Drug metabolism
drug DRUGBANK Nonoxynol-9
drug DRUGBANK Pidolic Acid
disease VO organization
drug DRUGBANK L-Aspartic Acid
drug DRUGBANK Guanosine
disease MESH coma
disease MESH tumor
drug DRUGBANK Carboxyamidotriazole
disease MESH infection
disease IDO host
drug DRUGBANK Fedratinib

Original Article

(Visited 1 times, 1 visits today)